Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency
- 1 March 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (5) , 1971-1972
- https://doi.org/10.1182/blood-2003-12-4331
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaBlood, 2004
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myelomaBlood, 2003
- CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic ApplicationsJournal of Immunotherapy, 2002